UnitedHealth Is Suing the Government Over Medicare Advantage Star Ratings

Published November 21, 2026, 12:58pm ET · 3 min read

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

A stethoscope lying on top of a document, an explanation of benefits document resting on a clipboard
© Thinkstock

Late on Thursday, November 19, 2026, UnitedHealth Group (NYSE:UNH | UNH Price Prediction) sued the Centers for Medicare & Medicaid Services (CMS) in federal court in Brunswick, Georgia. The suit challenges its 2027 Medicare Advantage star ratings. The company alleges that CMS improperly used 26 measures to rate 45 of its contracts. It says the agency either lacked the legal authority to do so, gave the company no chance to object, or both.

UnitedHealth says those contracts would score at least half a star and up to 1.5 stars higher if CMS calculated them correctly. The court has not ruled, and CMS declined to comment.

The stock closed Friday, November 20, at $339.85, up 2.84%, while the S&P 500 fell 3.70%. That gain followed a 5.6% drop on Thursday, which came amid concerns about a proposed CMS audit crackdown and Medicare expansion plans. TD Cowen also upgraded the shares to Buy on Friday morning, so the lawsuit alone does not explain the move. In after-hours trading, the stock was at $335.50, down 1.35%, and that price can change before Monday’s open.

What the Lawsuit Actually Claims

CMS rates plans from 1 to 5 stars, and contracts with at least four stars earn government bonus payments. A half-star swing matters most for a contract sitting just under four stars, because crossing that line unlocks bonus money that pays for richer benefits and lower premiums.

The complaint calls the ratings the government’s “principal signal” to patients about plan quality. It warns that low ratings could cut benefits and raise premiums. UnitedHealth said it did not take the step lightly and still wants to work with CMS on the Stars program. The company has disclosed no dollar figure for what it stands to lose.

How Much Medicare Matters to UnitedHealth

UnitedHealth had about 7.61 million Medicare Advantage members as of September 30, which an industry estimate puts at roughly 30% of the market. Its Medicare & Retirement unit brought in $42.42 billion[1] of third-quarter revenue, out of $112.694 billion for the whole company.

Medicare Advantage membership had already fallen by 935,000[1] since the end of 2025, and lower star ratings make it harder to keep members. Seniors are picking plans with these ratings in front of them until enrollment closes on December 7.

Fifteen Lawsuits Point to a Fight Over CMS’s Math

By one count, UnitedHealth is at least the 15th plan to sue CMS over the 2027 ratings. The case went to U.S. District Judge Lisa Godbey Wood, who is also hearing the suit CVS Health (NYSE:CVS) filed in October. CVS has said it could lose more than $2 billion in bonus payments and rebate retention, but that estimate applies only to CVS.

In May, Judge Wood ruled that CMS had miscalculated the rating for Clover Health (NASDAQ:CLOV) and ordered a recalculation. That opinion is UnitedHealth’s strongest legal point. Still, a recalculation does not guarantee a bonus, and no one knows when an opinion will come.

The lawsuit also risks UnitedHealth’s relationship with CMS, because the company is suing the agency that sets its bonuses at the same time that agency is considering an audit crackdown.

What Could Drive UNH Stock From Here

At 17 times forward earnings, the price already reflects the audit and policy fears behind a two-day drop of about 15% through Thursday. In October, management also raised its full-year adjusted EPS outlook to at least $20.50[1].

TD Cowen raised its target to $455 from $402. The consensus target of $476.16 reflects 6 Strong Buy, 15 Buy and 5 Hold ratings, with no Sell ratings. To close that gap, CMS needs to soften the audit plan, and the lawsuit needs to avoid hurting the working relationship.

UNH analyst ratings
UNH price target

Watch for an opinion or recalculation order from Judge Wood in the CVS or UnitedHealth case, or CMS agreeing on its own to recalculate. If CMS finalizes the audit crackdown with no recalculation, the bullish case is wrong.

Contact [email protected] for any questions or corrections.

Omor Ibne Ehsan

Omor Ibne Ehsan is a writer at 24/7 Wall St. He is a self-taught investor with a focus on growth, cyclical, and dividend equities that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as penny stocks.

All articles →

Sources

  1. UnitedHealth Group Form 8-K (Q3 FY2026)U.S. Securities and Exchange Commission